important piece to the puzzle, reporting their analysis of a large contemporary Swedish cohort study using national registries. The authors found an increased severity of disease at presentation with an incident acute coronary syndrome (ACS) and worse shortterm all-cause mortality in patients with active RA compared with matched controls. Interestingly, worse outcome in patients with RA compared with matched controls persisted after adjustment for clinical covariates, including the type of ACS. Moreover, among deaths, the majority of cases had a cardiac cause (89.9% vs. 90.8%). Of note, all-cause mortality during the first 30 days after an ACS was quite high in patients with RA (15.7%) compared with matched controls (10.7%), likely attributable to the surprisingly advanced age in this cohort (median age 73.8 vs. 73.6 years). Altogether, these findings support the notion of an aggravated course of coronary atherosclerosis and ACS in patients with RA.
RA and atherosclerosis as the underlying cause of coronary artery disease share several features in pathophysiology, genetic predisposition and risk factors, assigning a central role to inflammation. 6 Indeed, like RA, atherosclerosis is a chronic inflammatory disease, specifically of the arterial wall. The dynamic nature of atherosclerosis is characterised by its evolution in several stages, culminating in plaque rupture or erosion with ensuing atherothrombosis and vascular occlusion as the pathophysiological culprit of an ACS. 7 Endothelial activation with expression of cell adhesion molecules occurs in arteries exposed to disturbed blood flow (i.e. bifurcations) and pro-inflammatory stimuli. Lipoprotein accumulation and oxidative modification in the subintimal space propagate expression of cell adhesion molecules and synthesis of pro-inflammatory cytokines and mediators by endothelial cells which, in turn, result in the recruitment and activation of various types of circulating leucocytes comprising neutrophils, monocytes and T cells (predominantly the T helper 1 subset). In the arterial intima, monocytes differentiate into macrophages and take up oxidised lipoproteins, converting them into foam cells. T cells can recognise specific antigens derived from these modified lipoproteins and orchestrate the immune response. Atherosclerotic lesion progression involves migration and proliferation of vascular smooth muscle cells in the intima and increased turnover of components of the extracellular matrix (i.e. collagen, elastin and proteoglycans) by matrix-degrading enzymes. Advanced stages of atherosclerotic plaques are characterised by a lipid core, an accumulation of extracellular lipids with cholesterol crystals derived from dead cells (i.e. foam cells and vascular smooth muscle cells), sealed on the luminal side by a fibrous cap separating it from circulating blood. These dynamic changes in plaque composition culminate in plaque rupture or erosion, followed by thrombus formation ( Figure 1A) . In RA, the inflammatory process in the synovial joint is characterised by endothelial activation with increased expression of adhesion molecules and infiltration of immune cells comprising T cells of the T helper 1 subset and monocytes. Cartilage degradation in the synovial joint constitutes the hallmark of RA, mediated by persistently activated fibroblast-like synoviocytes (FLS) that express matrix-degrading enzymes. The combination of degradation products from the extracellular matrix exposing antigens that can be recognised by T cells and 12 and patients with RA 13 showed clonal restriction when compared with controls. These findings indicate similar autoimmune responses against specific antigens in ACS and RA alike. Anti-inflammatory drugs have been used for a long time in patients with RA and the anti-metabolite methotrexate was associated with a reduction in cardiovascular events in a recent meta-analysis.
14 Among the novel anti-inflammatory biologic agents used in patients with RA, it will be interesting to learn about the effects on cardiovascular outcomes during long-term follow-up of therapeutic inhibition of tumour necrosis factor-a, inhibition of interleukin-1b or antagonism of the interleukin-6 receptor, respectively. In turn, in patients with coronary artery disease, ongoing trials are evaluating the effects on cardiovascular events of methotrexate and inhibition of interleukin-1b. 7, 15 It will be of great interest whether these trials confirm or refute the inflammatory hypothesis presented.
